Mycophenolate mofetil: New applications for this immunosuppressant

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 1, 2003, Pages 15-20

  Moder, Kevin G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTACID AGENT; AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SULFAMETHOXAZOLE; DRUG DERIVATIVE;

ALOPECIA; ANEMIA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CATARACTOGENESIS; COMPARATIVE TOXICOLOGY; CYTOPENIA; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER TOXICITY; LUNG FIBROSIS; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT INDICATION; URINARY EXCRETION; WEIGHT GAIN; AUTOIMMUNE DISEASE; DOSE RESPONSE; FORECASTING; RISK FACTOR;

AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MYCOPHENOLIC ACID; RISK FACTORS;

EID: 0037263903     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63607-1     Document Type: Review

References (39)

1. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997;54: 285-294.
2. CellCept Oral Suspension. Roche Laboratories. Physicians' Desk Reference: Micromedex Healthcare Series. Micromedex, Greenwood Village, CO (Edition expires June 2002). Vol. 112 [serial online]. Retrieved April 10, 2002, from the World Wide Web: http://www.micromedex.com.
3. Behrend M. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation. BioDrugs 2001;15:37-53.
4. Hunt SA. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus. Cardiol Rev 2000;8:180-184.
5. McDiarmid SV. Mycophenolate mofetil as induction therapy after liver transplantation. Liver Transpl Surg 1999;5(Suppl): S85-S89.
6. Matteson EL, Hickey AR, Maguire L, et al. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-814.
7. Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99:276-281.
8. McMurray RW, Elbourne KB, Lal S. Mycophenolate mofetil prevents lupus nephritis and mortality in female B/W mouse model of SLE. Arthritis Rheum 1997;40(Suppl):S324.
9. Corna D, Morigi M, Facchinetti D, et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997;51:1583-1589.
10. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998;9:1407-1415.
11. Jonsson CA, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRL1pr/1pr mice. Clin Exp Immunol 1999;116:534-541.
12. Jonsson CA, Erlandsson M, Svensson L, et al. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRL1pr/1pr mice. Cell Immunol 1999;197:136-144.
13. Zoja C, Benigni A, Noris M, et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001;60:653-663.
14. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-839.
15. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162.
16. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318-322.
17. Karassa FB, Isenberg DA. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2001;344:382-383.
18. Adu D. The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol Dial Transplant 2001;16: 1536-1538.
19. Gordon C, Cross J, Jayne D. Prospective study of remission induction by mycophenolate mofetil in lupus nephritis. Arthritis Rheum 2001;44(Suppl):S280-S281.
20. Falk RJ. Treatment of lupus nephritis-a work in progress. N Engl J Med 2000;343:1182-1183.
21. Fu YF, Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Clin Nephrol 2001;55:318-321.
22. Buratti S, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-2108.
23. Imundo LF, Ebner-Lyon L, Li SC, et al. An increased relapse rate in the second year follow-up of mycophenolate mofetil therapy in childhood SLE. Arthritis Rheum 2001;44(Suppl):S261.
24. Gaubitz M, Schorat A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-736.
25. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001;137:235-236.
26. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11(Suppl):S117-S119.
27. Grundmann-Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000;42:835-837.
28. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001;202:341-343.
29. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of four cases. J Rheumatol 2000;27:1542-1545.
30. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
31. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001;40:84-88.
32. Waiser J, Budde K, Braasch E, Neumayer HH. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis 1999;34:e9.
33. Cohen Tervaert JW, Stegeman CA, Kallenberg CG. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Nephrol Hypertens 2001;10:211-217.
34. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999;40:265-268.
35. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000;6:16-20.
36. Miehsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001;96:782-787.
37. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000;95: 1201-1207.
38. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-971.
39. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-1195.